Grant: Project Grant
Ottawa Hospital Research Institute
$3,460,341.00
StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)
FY 2018-19
Summary
Rosuvastatin belongs to a family of drugs called statins. They are prescribed for patients with elevated cholesterol levels and have been found to decrease the incidence of arterial events such as heart attack and stroke. It is possible that statins may also be useful for the prevention of blood clots in the veins and for prevention of complications in the legs following a blood clot. However, little research has been done to investigate this potential.
In this trial, patients who have had a blood clot in the veins will be treated and evaluated in 2 groups: those who received rosuvastatin (20mg tablet per day) and those who received a placebo (a substance that has no therapeutic effect). We will compare the clinical outcomes in the two groups, specifically venous blood clots, arterial events such as heart attack and stroke, and long-term symptoms in the legs (post-thrombotic syndrome) to determine if there is a benefit to receiving rosuvastatin. We will also assess the
safety of rosuvastatin in this group of patients and the rates of side effects that are reported.
Department
Program
Project Grant
Recipient
Location
Ontario, Canada
Recipient Type
Other
Type
Grant
Source
CIHR Funding Decisions Database
As published
Id
401772
Name
Delluc Aurelien
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Clinical
Prcname2
Randomized Controlled Trials
Projecttitle
StAtins for Venous Event Reduction in patients with venous thromboembolism (The SAVER Trial)
Programtype2
Operating Grants
Orgnameinp2
Ottawa Hospital Research Institute
Cihramount2
$3,460,341
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Adjuvent; Arterial Vascular Events; Deep Vein Thrombosis; Post-Thrombotic Syndrome; Pulmonary Embolism; Randomized Controlled Trial; Rosuvastatin; Secondary Prevention; Statin; Venous Thromboembolism
Abstract
Rosuvastatin belongs to a family of drugs called statins. They are prescribed for patients with elevated cholesterol levels and have been found to decrease the incidence of arterial events such as heart attack and stroke. It is possible that statins may also be useful for the prevention of blood clots in the veins and for prevention of complications in the legs following a blood clot. However, little research has been done to investigate this potential.
In this trial, patients who have had a blood clot in the veins will be treated and evaluated in 2 groups: those who received rosuvastatin (20mg tablet per day) and those who received a placebo (a substance that has no therapeutic effect). We will compare the clinical outcomes in the two groups, specifically venous blood clots, arterial events such as heart attack and stroke, and long-term symptoms in the legs (post-thrombotic syndrome) to determine if there is a benefit to receiving rosuvastatin. We will also assess the
safety of rosuvastatin in this group of patients and the rates of side effects that are reported.
Competitiondate
201903
Approvedterm2
5 yrs 0 mth
Pinamesdelim
Delluc, Aurelien; Rodger, Marc A
Approvedterm
5 ans 0 mois
Cihrcontribution2
~ $3,460,341~ $0~
